Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
What is Genetic Engineering?00:49

What is Genetic Engineering?

Overview
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of Metabolic Syndrome in Male Fertility: Is It a Risk Factor?

Archivos espanoles de urologia·2025
Same author

Exploring the Association Between Varicocele and Testosterone Deficiency in Men Over 50 Years of Age.

Urology·2025
Same author

Psychological and Pain Factors in Microsurgical Testicular Sperm Extraction (Micro-TESE) for Non-Obstructive Azoospermia: A Comparative Study of Successful and Unsuccessful Cases.

Urology journal·2024
Same author

Delineating patient errors in an intracavernosal injection program.

The journal of sexual medicine·2024
Same author

Painless penile periurethral polymicrobial abscess causing urinary retention.

Urology case reports·2022
Same author

A National Analysis of Temporal Changes in Prescribing of Testosterone Replacement Therapy Considering Methods of Delivery and Government Regulation.

The world journal of men's health·2020

Related Experiment Videos

Gene therapy for erectile dysfunction: fact or fiction?

Muammer Kendirci1, Patrick E Teloken, Hunter C Champion

  • 1Department of Urology, Sisli Etfal Training and Research Hospital, Istanbul, Turkey.

European Urology
|September 5, 2006
PubMed
Summary

Gene therapy offers a promising new approach for treating erectile dysfunction (ED), especially in difficult-to-treat populations. Research indicates that gene therapy strategies are feasible and effective for improving erectile function.

Related Experiment Videos

Area of Science:

  • Urology
  • Regenerative Medicine
  • Molecular Biology

Background:

  • Erectile dysfunction (ED) significantly impacts patient quality of life.
  • Current treatments like phosphodiesterase type 5 inhibitors (PDE5-Is) are not effective for all patients, particularly those with diabetes or post-prostatectomy.
  • Novel therapeutic strategies are needed for refractory ED cases.

Purpose of the Study:

  • To explore the potential of gene therapy for treating erectile dysfunction.
  • To review gene therapy targets, vectors, and strategies for specific ED etiologies.
  • To assess the feasibility of gene therapy for difficult-to-treat ED populations.

Main Methods:

  • Discussion of gene therapy principles applied to ED.
  • Identification of potential gene targets and signaling pathways involved in erection.
  • Review of suitable vectors for gene delivery to penile tissues.
  • Consideration of gene therapy for ED associated with diabetes, aging, vascular insufficiency, and nerve injury.

Main Results:

  • The penis is an accessible target for gene therapy due to its external location and vascular characteristics.
  • Key signaling pathways for penile erection, including nitric oxide/cyclic guanosine monophosphate and RhoA/Rho-kinase, are targets for gene therapy.
  • Gene therapy approaches also focus on growth factors, ion channels, peptides, and oxidative stress modulation.

Conclusions:

  • Novel treatment modalities are required for patients with ED who do not respond to conventional therapies.
  • Gene therapy presents a feasible and promising novel approach for treating erectile dysfunction.
  • Preclinical and clinical studies support the potential of gene therapy for ED treatment.